Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
-
Noosa News15 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News13 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News23 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common